Table 2

MMP and TIMP production in BM-MNCs from patients with AMLa

Patient no.Sex/ageDiagnosisPrimary diseaseBlasts (%)Enzyme releaseExpression
BMPBMMP-2MMP-9MMP-9TIMP-1
1F/46AML-M18893++
2F/32AML-M2610++
3F/29AML-M2305NDND
4F/38AML-M2642++
5F/58AML-M26680++
6M/65AML-M23333NDND
7M/25AML-M24374++
8M/60AML-M38562++
9F/43AML-M44515++
10M/39AML-M58597++
11M/71AML-M5920NDND
12F/71sAMLMDS702++
13M/71sAMLMDS6216NDND
14M/66sAMLMDS364+++
15F/30sAMLMDS319+++
16M/69sAMLMDS5945++
17F/53sAMLOMF9084++
18F/76sAMLPV6033++
19M/73sAMLTC563++++
20F/39AML-remAML-M320+++
21F/50AML-remAML-M320NDND
22M/33AML-remAML-M420NDND
23M/31AML-remAML-M540++
24F/65AML-remMDS20++
  • a BM, bone marrow; PB, peripheral blood; sAML, secondary AML; M1–M5, FAB classification; rem, in remission; OMF, osteomyelofibrosis; PV, polycythemia vera; TC, thyroid carcinoma; •, activity detected by zymography; ○, no activity detected; +++, very strong signal (PSL >0.5); ++, strong signal (PSL = 0.1–0.5); +, weak signal (PSL <0.1); ND, not determined.